Therefore, this study aimed to assess the prognostic performance of a modified HFA-ICOS tool in a large, general cancer population, and in subgroups receiving anthracyclines, human epidermal growth factor receptor 2 (HER2)-targeted therapy, vascular endothelial growth factor (VEGF) inhibitors and myeloma therapy. This evidence concerns the gene ERBB2 and plasma cell myeloma.